HER2 positivity predicts a benefit from paclitaxel treatment after adjuvant chemotherapy
Sudeep Gupta
Correspondence Tata Memorial Hospital, Dr E Borges Road, Parel, Mumbai 400012, India
Email sudeepgupta@tatahospital.net
This article has no abstract so we have provided the first paragraph of the full text.
A series of randomized studies published in the past 10 years have established taxane-containing anthracycline regimens as a standard adjuvant treatment option in women with high-risk breast cancer. The addition of taxanes (e.g. paclitaxel or docetaxel) to anthracyclines is, however, associated with adverse effects such as myelosuppression, neuropathy and fluid retention as well as additional treatment costs. It is, therefore, of great interest to know which, if any, subgroup of patients would preferentially benefit from the addition of a taxane. A number of correlative studies have recently sought to answer the question of preferential benefit from various treatments for breast cancer.1
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.